+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06958679

Phase I Study of SYS6005 to Evaluate Safety and Effectiveness in Adults With Advanced Malignant Tumors

Led by CSPC Megalith Biopharmaceutical Co.,Ltd. · Updated on 2025-05-14

132

Participants Needed

1

Research Sites

73 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating SYS6005, an investigational drug, in adults with advanced malignant tumors, including both solid tumors and B-cell malignancies. This Phase I, open-label, multicenter study aims to assess the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumor activity of SYS6005. The study includes patients who have failed standard therapies or are intolerant to them, focusing on determining the maximum tolerated dose and recommended Phase 2 dose of SYS6005. The study consists of two phases a dose-escalation phase using an accelerated titration design across seven dose levels with 21-day cycles, and a dose-expansion phase where selected doses and tumor types are further explored. Participants receive SYS6005 intravenously on Day 1 of each 21-day cycle. Treatment continues until disease progression, unacceptable side effects, or other reasons for stopping. Dose adjustments are guided by a Safety Monitoring Committee. Participants will undergo safety monitoring including adverse event reporting, laboratory tests, and performance status evaluations. Efficacy is assessed using imaging studies. Blood samples are collected to study pharmacokinetics and immune responses, including anti-drug antibodies. Survival is followed quarterly until death or study completion. The study may last up to 12 months or longer depending on treatment duration and follow-up needs.

CONDITIONS

Brief Title

Evaluation of SYS6005 in Patients With Advanced Malignant Tumor

Research Team

C

Clinical Trials Information Group officer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here